title: [Sequelae of deep venous thrombosis, 5-year follow-up of 341 patients].
abstract: In order to see whether thrombolytic therapy led to a reduction of CPT, a cause of long periods of inability to work, a study on the development of phlebothrombosis was carried out at the Department of Angiology at the Hospital Cantonal of Basle. Subjects presenting deep phlebothrombosis, either acute or sub-acute, were observed after 5 years... Or the 341 patients, 208 received streptokinase and 133 heparin. After the 5 years, 1 in 5 patients had developed CPT. The incidence of CPT was above all related to the extent of the thrombosis. If one considers not only the immediate therapeutic effect but also the extent of the thrombosis, then the incidence of CPT, especially in leg ulcers, is roughly twice as high in patients with extensive thromboses, and therapy is negative, as in the patients with thromboses limited to two stages only, in which group the therapy is positive. It has even been eliminated where the thrombosis had been limited to the leg. Prophylactic measures are therefore necessary in the groups at high risk. The diagnosis must be swift in order to commence correct therapy whilst the thrombosis is not as yet extensive. Heparin therapy seems to be enough for those thromboses limited to the leg. Whilst awaiting thrombolytic methods without serious side-effects, thrombolytic treatment should be reserved for extensive thromboses in young patients with no contraindications. It is a condition sine qua non that the patient and the parameters of coagulation should be monitored.
authors.forename: M T
authors.initials: MT
authors.lastname: Widmer
authors.forename: E
authors.initials: E
authors.lastname: Zemp
authors.forename: R
authors.initials: R
authors.lastname: Voëlin
authors.forename: E
authors.initials: E
authors.lastname: Brandenberg
authors.forename: A
authors.initials: A
authors.lastname: Da Silva
mesh_terms: D005260:Female; D005500:Follow-Up Studies; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011186:Postphlebitic Syndrome / Q000209:etiology*; D013300:Streptokinase / Q000627:therapeutic use; D013924:Thrombophlebitis / Q000150:complications* / Q000188:drug therapy
chemical_list: D006493:Heparin; D013300:Streptokinase
vernacular_title: Suites de la phlébothrombose profonde, bilan au bout de 5 années, chez 341 malades.